EMA has published guidance to help pharmaceutical companies prepare for the UK withdrawal from the EU. The document outlines the practical and simplified requirements companies should follow when they apply for changes to their marketing authorization for the continued marketing of their medicine in the European Economic Area after the UK withdrawal. EMA is preparing a series of further Brexit-related guidances which will be published on its website. Companies are advised to regularly check EMA’s dedicated webpage on the consequences of Brexit.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
